skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

100+ Total results for product and free and sample content found

Scrip

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

By Ian Schofield 29 Nov 2022

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Topic Cancer

In Vivo

Bayer’s US Playbook: The Smart Way To Top-Line Growth

By William Looney 14 Nov 2022

Bayer’s US Playbook: The Smart Way To Top-Line Growth

The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.

Topic Business Strategies Company Analysis

Medtech Insight

Inside Toyota's 'Cult' Car-Makers Quality VP Tells Device-Makers How To Adopt 4-Pronged Quality Strategy

By Shawn M. Schmitt 14 Nov 2022

Inside Toyota's 'Cult' Car-Makers Quality VP Tells Device-Makers How To Adopt 4-Pronged Quality Strategy

Toyota Motor North America's Kristen Tabar told a roomful of medical device quality and regulatory professionals at a Case for Quality forum that they can infuse quality concepts into every nook and cranny of their firms by adopting the car-maker's quality strategy of reflection, education, celebration and planning. "I don’t want to make it sound like it’s sort of cult-y, but it’s kind of cult-y," Tabar quipped.

Topic Company Analysis Strategy

Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

By Jessica Merrill 14 Nov 2022

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Topic Coronavirus Vaccines Sales Earnings

Scrip

Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

By Jessica Merrill 14 Nov 2022

Article

Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.

Topic Business Strategies Immune Disorders Inflammation

Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 14 Nov 2022

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Topic Cell & Gene Therapy Drug Development Landscape

Generics Bulletin

Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

By David Wallace 25 Oct 2022

Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.

Topic Company Analysis

Scrip

AstraZeneca Plans $630m Korea Investment Amid Favorable Policies

By Jung Won Shin 25 Oct 2022

AstraZeneca Plans $630m Korea Investment Amid Favorable Policies

AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.

Topic Company Analysis Strategy

Citeline Connect

Survey Results: The Impact of Compensation on Clinical Trial Participation

06 Oct 2022

impact-compensation-cover

In creating custom websites that share information about clinical trials, Citeline Connect recognized the need to incorporate the patient voice during the design stage. Citeline Connect partnered with Savvy Cooperative, which assembled a patient panel to provide candid feedback on the end-user experience.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: